# A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

> **NCT06717126** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **iOnctura** · enrollment: 85 (estimated)

## Conditions studied

- Uveal Melanoma
- Ocular Melanoma

## Interventions

- **DRUG:** roginolisib
- **DRUG:** Investigator choice of standard therapy

## Key facts

- **NCT ID:** NCT06717126
- **Lead sponsor:** iOnctura
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717126, "A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06717126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*